UBS AM
PTGX icon

UBS AM’s Protagonist Therapeutics PTGX Stock Holding History

UBS AM’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Sell
107,094
-343
-0.3% -$35.8K ﹤0.01% 1111
2026
Q1 		$11.3M Buy
107,437
+2,909
+3% +$258K ﹤0.01% 1131
2025
Q4 		$9.13M Sell
104,528
-5,701
-5% -$467K ﹤0.01% 1161
2025
Q3 		$7.32M Sell
110,229
-133,144
-55% -$7.57M ﹤0.01% 1190
2025
Q2 		$13.5M Buy
243,373
+34,617
+17% +$1.66M ﹤0.01% 1213
2025
Q1 		$10.1M Sell
208,756
-79,155
-27% -$3.32M ﹤0.01% 1222
2024
Q4 		$11.1M Sell
287,911
-80,221
-22% -$3.5M ﹤0.01% 1199
2024
Q3 		$16.6M Sell
368,132
-1,823
-0.5% -$73.7K ﹤0.01% 1024
2024
Q2 		$12.8M Buy
369,955
+34,637
+10% +$1.01M ﹤0.01% 1035
2024
Q1 		$9.7M Buy
335,318
+46,239
+16% +$1.26M ﹤0.01% 1013
2023
Q4 		$6.63M Buy
289,079
+218,020
+307% +$3.81M ﹤0.01% 1141
2023
Q3 		$1.19M Buy
71,059
+6,281
+10% +$122K ﹤0.01% 1867
2023
Q2 		$1.49M Hold
64,778
– – ﹤0.01% 1817
2023
Q1 		$1.49M Buy
+64,778
New +$1.09M ﹤0.01% 1817
2022
Q4 		– Sell
-27,275
Closed -$230K – 2706
2022
Q3 		$230K Sell
27,275
-5,389
-16% -$51K ﹤0.01% 2563
2022
Q2 		$258K Hold
32,664
– – ﹤0.01% 2513
2022
Q1 		$773K Hold
32,664
– – ﹤0.01% 2269
2021
Q4 		$1.12M Buy
32,664
+5,066
+18% +$160K ﹤0.01% 2153
2021
Q3 		$489K Hold
27,598
– – ﹤0.01% 2511
2021
Q2 		$1.24M Buy
27,598
+2,598
+10% +$85.8K ﹤0.01% 2095
2021
Q1 		$648K Buy
25,000
+12,800
+105% +$324K ﹤0.01% 2292
2020
Q4 		$246K Buy
+12,200
New +$263K ﹤0.01% 2458

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS AM's PTGX Position: Q2 2026 in Review

UBS AM reduced its Protagonist Therapeutics (PTGX) stake by 0.32% in Q2 2026, selling an estimated $35.8K and leaving 107,094 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

UBS AM first reported a position in PTGX in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.6M in Q3 2024. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • UBS AM held 107,094 shares of Protagonist Therapeutics worth $13.1M as of Q2 2026.
  • UBS AM sold 343 Protagonist Therapeutics shares in Q2 2026, an estimated $35.8K.
  • Protagonist Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1111 holding.
  • UBS AM first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • UBS AM's Protagonist Therapeutics position peaked at $16.6M in Q3 2024.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.